Article Text

A pregnant patient with a positive hepatitis B surface antigen
  1. Arjmand Rasool Mufti1,
  2. Nancy Reau2
  1. 1Department of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, Chicago, Illinois, USA
  2. 2Center for Liver Disease, University of Chicago Medical Center, Chicago, Illinois, USA
  1. Correspondence to Dr Nancy Reau, Center for Liver Disease, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 7120, Chicago, IL 60637, USA; nreau{at}


Hepatitis B is a major cause of liver disease worldwide. The highest rates of chronic infection occur in subjects who are infected early in life and these patients are also at the greatest risk of developing complications such as hepatocellular carcinoma and cirrhosis from the disease. There has been a concerted worldwide effort to immunise newborns that are at the highest risk of acquiring infection. In 1992, when WHO recommended global vaccination against hepatitis B, only 31 countries elected to participate in the programme. By 2009, 177 countries were part of WHO national infant immunisation programme. Consequently, maternal screening and infant immunoprophylaxis have significantly reduced vertical transmission of hepatitis B. In this paper, we will review the management of hepatitis B in the pregnant population and identify some of the challenges that are encountered in this specialised population.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.